Zacks Research Issues Positive Outlook for Pfizer Earnings

Pfizer Inc. ( NYSE:PFE – Free Report ) – Investment analysts at Zacks Research boosted their Q1 2026 earnings estimates for shares of Pfizer in a report issued on Tuesday, January 21st. Zacks Research analyst K.

Shah now forecasts that the biopharmaceutical company will earn $0.64 per share for the quarter, up from their prior estimate of $0.63.



The consensus estimate for Pfizer’s current full-year earnings is $2.94 per share. Zacks Research also issued estimates for Pfizer’s Q2 2026 earnings at $0.

62 EPS. Several other equities analysts have also issued reports on PFE. Bank of America restated a “neutral” rating and set a $29.

00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th.

They issued a “market perform” rating and a $32.00 target price on the stock. StockNews.

com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Truist Financial dropped their price objective on Pfizer from $36.00 to $32.

00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.

00 price target for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.

com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.00. Pfizer Trading Down 1.

3 % NYSE PFE opened at $26.10 on Friday. Pfizer has a 12 month low of $24.

48 and a 12 month high of $31.54. The stock has a 50-day simple moving average of $26.

11 and a 200 day simple moving average of $27.94. The company has a current ratio of 1.

00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

The company has a market capitalization of $147.89 billion, a PE ratio of 35.27, a P/E/G ratio of 0.

64 and a beta of 0.64. Pfizer ( NYSE:PFE – Get Free Report ) last announced its quarterly earnings data on Tuesday, October 29th.

The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.

42. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.

92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.

28%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis.

During the same period last year, the firm earned ($0.17) earnings per share. Pfizer Increases Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th.

Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.

42. This represents a $1.72 annualized dividend and a yield of 6.

59%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is presently 227.

03%. Insiders Place Their Bets In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average cost of $28.

24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400.

This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink .

Insiders own 0.06% of the company’s stock. Institutional Investors Weigh In On Pfizer Several hedge funds have recently bought and sold shares of PFE.

Fred Alger Management LLC grew its holdings in Pfizer by 6.6% in the 2nd quarter. Fred Alger Management LLC now owns 95,592 shares of the biopharmaceutical company’s stock valued at $2,675,000 after buying an additional 5,932 shares in the last quarter.

Caxton Associates LP acquired a new position in shares of Pfizer in the second quarter valued at about $738,000. AXA S.A.

increased its position in Pfizer by 4.9% during the second quarter. AXA S.

A. now owns 2,632,380 shares of the biopharmaceutical company’s stock worth $73,654,000 after acquiring an additional 123,605 shares during the period. AQR Capital Management LLC raised its stake in Pfizer by 1.

6% in the 2nd quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock worth $17,068,000 after purchasing an additional 9,435 shares in the last quarter. Finally, Drucker Wealth 3.

0 LLC bought a new stake in Pfizer in the 2nd quarter valued at about $2,782,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer ( Get Free Report ) Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. Featured Articles Five stocks we like better than Pfizer How to buy stock: A step-by-step guide for beginners Bloom Energy: Powering the Future With Decentralized Energy ESG Stocks, What Investors Should Know Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul 3 Dividend Kings To Consider Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.

com's FREE daily email newsletter ..